Patrick Harrington
Overview
Explore the profile of Patrick Harrington including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
657
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duminuco A, Au Yeung J, Vaghela R, Virdee S, Woodley C, Asirvatham S, et al.
Hemasphere
. 2024 Aug;
8(8):e143.
PMID: 39131900
No abstract available.
2.
Duminuco A, Harrington P, Harrison C, Curto-Garcia N
Blood Lymphat Cancer
. 2023 Dec;
13:77-90.
PMID: 38146420
Polycythemia vera (PV) is a subtype of myeloproliferative neoplasms characterized by impaired quality of life and severe complications. Despite the increasingly in-depth knowledge of this condition, it necessitates a multifaceted...
3.
Gadaleta M, Harrington P, Barnhill E, Hytopoulos E, Turakhia M, Steinhubl S, et al.
NPJ Digit Med
. 2023 Dec;
6(1):229.
PMID: 38087028
Early identification of atrial fibrillation (AF) can reduce the risk of stroke, heart failure, and other serious cardiovascular outcomes. However, paroxysmal AF may not be detected even after a two-week...
4.
Harrington P, Dillon R, Radia D, Rousselot P, McLornan D, Ong M, et al.
Haematologica
. 2023 Jan;
108(6):1555-1566.
PMID: 36700403
Dasatinib is a multi-kinase inhibitor with activity against the SRC kinase LCK, which plays a critical role in T-cell receptor signaling. Dasatinib, initially developed as an immunosuppressive agent, is by...
5.
Okikiolu J, Woodley C, Cadman-Davies L, OSullivan J, Radia D, Garcia N, et al.
Leuk Res Rep
. 2023 Jan;
19:100360.
PMID: 36590864
Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b...
6.
Harrington P, Kurshan A, Delord M, Lechmere T, Sheikh A, Saunders J, et al.
Blood Adv
. 2022 Sep;
7(10):1954-1957.
PMID: 36083126
No abstract available.
7.
Harrington P, Dillon R, Radia D, McLornan D, Woodley C, Asirvatham S, et al.
Br J Haematol
. 2022 Jul;
198(6):1011-1015.
PMID: 35802024
The search for novel targets in chronic myeloid leukaemia (CML) is ongoing, to improve treatment efficacy in refractory disease and increase eligibility for tyrosine kinase inhibitor (TKI) discontinuation. Increased frequency...
8.
Harrington P, Doores K, Saunders J, de Lord M, Saha C, Lechmere T, et al.
Blood Cancer J
. 2022 Apr;
12(4):73.
PMID: 35459222
No abstract available.
9.
Harrington P, Doores K, Saha C, Saunders J, Child F, Dillon R, et al.
Cancer Cell
. 2021 Dec;
39(12):1654.
PMID: 34906318
No abstract available.
10.
Harrington P, Doores K, Saha C, Saunders J, Child F, Dillon R, et al.
Cancer Cell
. 2021 Oct;
39(11):1448-1449.
PMID: 34717827
No abstract available.